The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2007Inhibition of c-Abl Tyrosine Kinase as a Novel Therapy to Prevent PD ProgressionObjective/Rationale: Mutations in the parkin gene cause early-onset autosomal recessive PD. We have discovered that parkin is modified by an oxidative-stress induced signaling kinase, c...
-
Rapid Response Innovation Awards, 2007Unraveling the genetic basis for alpha-synuclein oligomerization in living cells using bimolecular fluorescence complementation
Oligomerization of alpha-synuclein is hypothesized to be the pathogenic mechanism of protein aggregate formation and cell death in neurons of PD patients. Dr. Outeiro proposes to develop an assay to...
-
Target Validation, 2007Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease
Objective/Rationale:
A major known risk factor in Parkinson’s disease is the misfolding, aggregation and abnormal accumulation of the protein alpha-synuclein. The goal of the proposed work is to... -
Rapid Response Innovation Awards, 2007Understanding the Role of Glucocerebrosidase in Parkinson's Disease Pathogenesis: Toward a New Genetic Model of Sporadic PD
Gaucher’s disease is a glycosphingolipid-storage disease in which homozygous mutations are found in the lysosomal enzyme glucocerebrosidase (GBA) gene. PD and Gaucher’s disease share many clinical and...
-
Rapid Response Innovation Awards, 2007Target Identification of the Mitochondrial Parkinson's Disease PTEN-Induced Kinase 1
Mutations in PINK1 can cause Parkinson’s disease in certain familial PD cases. The exact cellular function of PINK1 and the impact of disease-relevant mutations remain unknown. PINK1 is known to...
-
Rapid Response Innovation Awards, 2007Development of SHG to Discover Drugs to Selectively Block AlphaS toxicity
Abnormal aggregation of normal or genetically mutated alpha-synuclein protein has been proposed as one possible mechanism for PD. Drugs that can target this abnormal change in the structure of the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.